BFM
ENVB icon

Boothbay Fund Management’s Enveric Biosciences ENVB Stock Holding History

Boothbay Fund Management’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.6K Buy
+30,142
New +$72.4K ﹤0.01% 2120
2022
Q2 		– Sell
-5
Closed -$15K – 2365
2022
Q1 		$15K Hold
5
– – ﹤0.01% 2230
2021
Q4 		$41K Buy
+5
New +$70.3K ﹤0.01% 1782

Other funds holding ENVB

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Boothbay Fund Management's ENVB Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 30,142 shares worth $41.6K. The stake represents ﹤0.01% of the portfolio and ranks #2120 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ENVB as recently as Q1 2022.

Boothbay Fund Management first reported a position in ENVB in Q4 2021 and has held it in 3 quarters since. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • Boothbay Fund Management held 30,142 shares of Enveric Biosciences worth $41.6K as of Q2 2026.
  • Enveric Biosciences was a new Boothbay Fund Management position in Q2 2026.
  • Enveric Biosciences made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2120 holding.
  • Boothbay Fund Management first reported a position in Enveric Biosciences in Q4 2021 and has held it in 3 quarters since.
  • 24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.